Dosing Information

Patients should complete the entire course of treatment as prescribed,
which consists of:

Morning Dose

One dose in the morning consisting of:

• Two 150-mg tablets of nirmatrelvir
• One 100-mg tablet of ritonavir

Evening Dose

One dose in the evening consisting of:

• Two 150-mg tablets of nirmatrelvir
• One 100-mg tablet of ritonavir

Dosage for PAXLOVID^TM (nirmatrelvir tablets; ritonavir tablets)

The dosage for PAXLOVID is 300 mg nirmatrelvir (two 150-mg tablets) with 100 mg ritonavir (one 100-mg tablet) with all 3 tablets taken together orally twice daily for 5 days. Prescriptions should specify the numeric dose of each active ingredient within PAXLOVID. Completion of the full 5-day treatment course and continued isolation in accordance with public health recommendations are important to maximize viral clearance and minimize transmission of SARS-CoV-2.

How Do Patients Take PAXLOVID?

PAXLOVID consists of 2 medicines: nirmatrelvir and ritonavir. Patients should take 2 tablets of nirmatrelvir (150 mg) with 1 tablet of ritonavir (100 mg) by mouth twice daily (in the morning and in the evening) for 5 days. For each dose, all 3 tablets should be taken at the same time.

• Inform patients to take PAXLOVID with or without food
• Advise patients to swallow all tablets for PAXLOVID whole and not to chew, break, or crush the tablets
• Alert the patient of the importance of completing the full 5-day treatment course and to continuing isolation in accordance with public health recommendations to maximize viral clearance and minimize transmission of SARS-CoV-2
• If the patient misses a dose of PAXLOVID within 8 hours of the time it is usually taken, the patient should take it as soon as possible and resume the normal dosing schedule. If the patient misses a dose by more than 8 hours, the patient should not take the missed dose and should instead take the next dose at the regularly scheduled time. The patient should not double the dose to make up for a missed dose
• If patients overdose on PAXLOVID, they should call their prescribing healthcare provider or go to the nearest hospital emergency room right away. Treatment of overdose with PAXLOVID should consist of general supportive measures, including monitoring of vital signs and observation of the clinical status of the patient. There is no specific antidote for overdose with PAXLOVID

NOTE: To ensure appropriate dosing in patients with moderate renal impairment, reduce the dosage of PAXLOVID to 150 mg nirmatrelvir and 100 mg ritonavir twice daily for 5 days. Providers should counsel patients about renal dosing instructions.

Dose Adjustments

Important Dosing Information in Patients with Renal Impairment
No dosage adjustment is needed in patients with mild renal impairment (eGFR ≥60 to <90 mL/min). In patients with moderate renal impairment (eGFR ≥30 to <60 mL/min), the dosage of PAXLOVID is 150 mg nirmatrelvir and 100 mg ritonavir twice daily for 5 days. Prescriptions should specify the numeric dose of each active ingredient within PAXLOVID. Providers should counsel patients about renal dosing instructions.

PAXLOVID is not recommended in patients with severe renal impairment (eGFR <30 mL/min) until more data are available; the appropriate dosage for patients with severe renal impairment has not been determined.


Use in Patients with Hepatic Impairment
No dosage adjustment is needed in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. No pharmacokinetics or safety data are available regarding the use of nirmatrelvir or ritonavir in subjects with severe hepatic impairment (Child-Pugh Class C); therefore, PAXLOVID is not recommended for use in patients with severe hepatic impairment.


Important Drug Interactions with PAXLOVID
Refer to other sections of the PAXLOVID Product Insert for important drug interactions with PAXLOVID. Interacting drugs listed are a guide and not considered a comprehensive list of all possible drugs that may interact with PAXLOVID. The healthcare provider should consult other appropriate resources such as the product label for the interacting drug for comprehensive information on dosing or monitoring with concomitant use of a strong CYP3A inhibitor such as ritonavir.Consider the potential for drug interactions prior to and during PAXLOVID therapy and review concomitant medications during PAXLOVID therapy [see Contraindications (4), Warnings and Precautions (5.1), and Drug Interactions (7) in the PAXLOVID Product Insert here].

Patients on ritonavir- or cobicistat-containing HIV or HCV regimens should continue their treatment as indicated. Monitor for increased PAXLOVID or protease inhibitor adverse events.

How the Product Is Supplied

Nirmatrelvir tablets and ritonavir tablets are supplied in separate cavities within the same child-resistant blister card.

Each carton of PAXLOVID contains 30 tablets divided in 5 daily-dose blister cards.

Each daily blister card contains 4 nirmatrelvir tablets (150 mg each) and 2 ritonavir tablets (100 mg each) and indicates which tablets need to be taken in the morning and evening.

How to verify your tablets are authentic

PAXLOVID must be prescribed by a licensed healthcare provider and supplied by a government approved pharmacy or medical facility.

Authentic PAXLOVID, from Pfizer Inc., will include the Pfizer name on the label and will be packaged in 5 aluminum push-through blister cards. Individual doses are not for sale. PAXLOVID will be packaged in a rectangular carton. The carton has a colorless, glossy coating that contains a repeated pattern of the Pfizer name and logo all over, and these repeating features are seen in a contrasting matte finish.

PAXLOVID consists of tablets for a 5-day oral treatment regimen, with morning and evening doses.

Pfizer is committed to patient safety and ensuring that people have accurate information about the investigational drug PAXLOVID, including how it is accessed and administered. We are actively monitoring for fraudulent offers of illegitimate PAXLOVID to protect patients from products that might be dangerous and lead to serious and life-threatening harm.

If you suspect the product you have received may be counterfeit, visit www.pfizer.com.hk/en/connect-with-us

Reference: Paxlovid (Nirmatrelvir, Ritonavir) Prescribing Information. Pfizer Corporation Hong Kong Limited Version May 2023